Strides Pharma Science Ltd Shows Technical Momentum Shift…
Technical Momentum and Indicator Overview
Strides Pharma Science Ltd (NSE: 688428) closed at ₹853.20 on 6 Mar 2026, marking a 2.57% increase from the previous close of ₹831.80. The stock traded within a range of ₹826.00 to ₹855.00 during the day, remaining well below its 52-week high of ₹1,024.90 but comfortably above the 52-week low of ₹551.00. This price action reflects a moderate recovery phase after a period of consolidation.
From a technical perspective, the daily moving averages have turned mildly bullish, suggesting short-term upward momentum. However, weekly and monthly MACD readings remain mildly bearish, indicating that the longer-term momentum has yet to fully confirm a sustained uptrend. The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, hovering in neutral territory and implying that the stock is neither overbought nor oversold.
Bollinger Bands present a mixed picture: weekly data remains mildly bearish, signalling some volatility and potential resistance near current levels, while monthly Bollinger Bands have shifted to bullish, hinting at a possible longer-term breakout if momentum sustains. The KST (Know Sure Thing) indicator remains bearish on the weekly chart and mildly bearish monthly, reinforcing the notion that momentum is still fragile and requires confirmation.
Other technical tools such as the Dow Theory and On-Balance Volume (OBV) offer a nuanced view. Weekly Dow Theory remains mildly bearish, but monthly readings have improved to mildly bullish, suggesting that accumulation might be occurring at higher timeframes. Similarly, OBV is mildly bearish weekly but mildly bullish monthly, indicating that volume trends could be supporting the recent price gains.
Mojo Score and Grade Upgrade
MarketsMOJO has upgraded Strides Pharma Science Ltd’s Mojo Grade from Sell to Hold as of 5 Mar 2026, reflecting an improved overall outlook. The company’s Mojo Score stands at 58.0, which is moderate and consistent with a Hold rating. The Market Cap Grade is 3, indicating a mid-cap status that often entails moderate liquidity and volatility. This upgrade suggests that while the stock is not yet a strong buy, it is showing signs of stabilisation and potential for further gains.
Price Performance Relative to Sensex
Strides Pharma’s price returns have outperformed the broader Sensex index over multiple time horizons, highlighting its strong relative strength despite recent technical caution. Over the past week, the stock declined by 1.05%, outperforming the Sensex’s 2.71% drop. Similarly, the one-month return was -0.76% versus Sensex’s -3.96%, and year-to-date the stock is down 5.45%, slightly better than the Sensex’s 6.11% decline.
Longer-term returns are particularly impressive. Over one year, Strides Pharma gained 37.48%, significantly outpacing the Sensex’s 8.53%. The three-year return is a remarkable 505.66%, dwarfing the Sensex’s 33.79% gain. Even over five and ten years, the stock has delivered 104.58% and 71.87% returns respectively, compared to the Sensex’s 58.74% and 224.65%. These figures underscore the company’s strong growth trajectory and resilience within the Pharmaceuticals & Biotechnology sector.
Sector Context and Outlook
Within the Pharmaceuticals & Biotechnology sector, Strides Pharma Science Ltd operates in a competitive and innovation-driven environment. The sector has faced headwinds from regulatory scrutiny and pricing pressures, but also benefits from increasing demand for generic medicines and biosimilars globally. The stock’s recent technical improvements and Mojo Grade upgrade suggest that investors are beginning to factor in these positive sectoral dynamics alongside company-specific strengths.
However, the mixed signals from technical indicators advise caution. The mildly bearish MACD and KST on weekly and monthly charts imply that momentum is not yet fully established. Investors should watch for confirmation through sustained price moves above key moving averages and a strengthening RSI. A break above the 52-week high of ₹1,024.90 would be a significant bullish signal, while failure to hold above current support levels near ₹830 could trigger renewed selling pressure.
Investor Takeaway
Strides Pharma Science Ltd’s recent technical parameter changes reflect a cautious but improving momentum profile. The upgrade in Mojo Grade to Hold and the mildly bullish daily moving averages provide a foundation for potential upside, especially if the stock can sustain gains above ₹850 and build volume support. However, the persistence of mildly bearish signals on weekly and monthly MACD and KST indicators suggests that investors should remain vigilant for signs of trend confirmation.
Given the stock’s strong long-term outperformance relative to the Sensex and its position within a dynamic sector, it remains an attractive candidate for investors with a medium to long-term horizon. Short-term traders may prefer to wait for clearer technical confirmation, particularly a sustained breakout above the 52-week high or a decisive improvement in momentum indicators such as RSI and MACD.
Overall, Strides Pharma Science Ltd is transitioning from a phase of technical caution to one of tentative optimism, making it a stock to watch closely in the coming weeks as market conditions evolve.
Get Started for only Rs. 16,999 – Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
